GGrantIndex
← Search

Population Sciences

$372,409P30FY2025CANIH

Roswell Park Cancer Institute Corp, Buffalo NY

Investigators

Linked publications, trials & patents

Trial NCT07082270Trial NCT06202066Trial NCT05589844Trial NCT05338905Trial NCT05292521Trial NCT05231122Trial NCT04607291Trial NCT04533542Trial NCT04530812Trial NCT04526587Trial NCT04379518Trial NCT04358315Trial NCT04348747Trial NCT04298606Trial NCT04290962Trial NCT04269213Trial NCT04231539Trial NCT04207190Trial NCT04119830Trial NCT04110249Trial NCT04109924Trial NCT04093323Trial NCT04081389Trial NCT04073745Trial NCT04068649Trial NCT04067830Trial NCT04060446Trial NCT04032418Trial NCT04000581Trial NCT03965234Trial NCT03935347Trial NCT03899987Trial NCT03897270Trial NCT03895918Trial NCT03881735Trial NCT03880422Trial NCT03879694Trial NCT03865472Trial NCT03851081Trial NCT03793907Trial NCT03789877Trial NCT03751449Trial NCT03751436Trial NCT03736720Trial NCT03735589Trial NCT03735095Trial NCT03727789Trial NCT03727061Trial NCT03709550Trial NCT03691376Trial NCT03688945Trial NCT03685695Trial NCT03683147Trial NCT03680235Trial NCT03679585Trial NCT03679559Trial NCT03678350Trial NCT03630601Trial NCT03574792Trial NCT03457142Trial NCT03403634Trial NCT03384836Trial NCT03358719Trial NCT03348748Trial NCT03333486Trial NCT03297489Trial NCT03211416Trial NCT03206047Trial NCT03192397Trial NCT03090412Trial NCT03017131Trial NCT03011736Trial NCT02965976Trial NCT02955290Trial NCT02953457Trial NCT02947386Trial NCT02877641Trial NCT02857374Trial NCT02853318Trial NCT02833506Trial NCT02713373Trial NCT02650986Trial NCT02575885Trial NCT02575508Trial NCT02531906Trial NCT02474095Trial NCT02455557Trial NCT02452463Trial NCT02414724Trial NCT02399215Trial NCT02393755Trial NCT02334865Trial NCT02287727Trial NCT02227940Trial NCT02170389Trial NCT02166905Trial NCT02159950Trial NCT02119728Trial NCT02100254Trial NCT02072486

Abstract

PROJECT SUMMARY (ABSTRACT) The overall goal of the Population Sciences (PS) Program is to reduce and prevent morbidity and mortality associated with cancer and its treatment, particularly among those in our catchment area, and to improve patients' quality of life. Our aims span the cancer continuum from primary prevention to epidemiological research on cancer risk relationships, and factors that influence cancer treatment outcomes which can be intervened upon to improve survivorship. Reducing cancer burden is a common cross-cutting element to each aim. Our aims are aligned with the Center's mission to eliminate cancer's grip on humanity through cancer research, cancer treatment, cancer prevention and cancer education. To address these goals, our research is driven by three specific aims: 1) to prevent cancer by intervening on modifiable risk factors, especially the burden of tobacco-related cancers, at the individual, regional, national, and global levels; 2) to understand cancer risk relationships, particularly at the molecular level and in populations; and 3) to investigate factors that influence cancer treatment outcomes and survivorship for insights into interventions to improve survival and enhance quality of life in our patients. The PS program continues to be co-led by Drs. Christine Ambrosone, and Andrew Hyland, who have complementary expertise that bridge these aims. Cutting-edge science includes studies in each of our aims that are policy impactful, practice changing, and paradigm shifting. Population Sciences members actively collaborate within and across the CCSG programs. We work closely with the Community Outreach and Engagement (COE) Office in all facets of the research process, including shaping the research direction of the program based on feedback from the Community Advisory Board, working together for study recruitment through the `ROCKstars' program, collecting surveillance and evaluation data in the community for needs assessments and tracking outcomes, and sharing research results with the community. Our members are actively engaged in Cancer Research Training and Education Coordination (CRTEC), providing training experiences for trainees at all levels, and participating in faculty training and career development programs provided by the CRTEC. The 38 members of the PS Program have $13.9M in peer-reviewed funding in 2023 (>3-fold increase from $3.8M in 2018) including $11.1M from NCI (also >3-fold increase from $3.0M in 2018), 15 large teams science grants, and 37 R01-type grants. Of the 965 publications since 2018, 22% were published in high-impact journals, 34% inter-programmatic, 33% intra-programmatic, and 53% collaborative with investigators at other institutions. In the coming cycle, PS members will continue to build upon their strengths and to expand into areas where there are current gaps with a goal to reduce cancer morbidity and mortality, particularly in our catchment area.

View original record on NIH RePORTER →